ErbB receptors: directing key signaling networks throughout life.

By Thomas Holbro, N. Hynes. Annual Review of Pharmacology and Toxicology, 2004

671 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/62a4b01a32d077cf22a506af930d52208701c50a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. N. Hynes
2. M. Lemmon
3. D. Leahy
4. Rina Plattner
5. Hyun-soo Cho
6. P. Dempsey
7. Divyamani Srinivasan
8. Huanhuan Chen

In Oncology

1. N. Hynes
2. D. Leahy
3. Rina Plattner
4. P. Dempsey
5. M. Lemmon
6. Divyamani Srinivasan
7. H. Ohtsu
8. S. Eguchi

In Radiology, Nuclear Medicine and Imaging

1. N. Hynes
2. J. Baselga

Citations in the corpus

• ADAMs as mediators of EGF receptor transactivation by G protein-coupled receptors. (2006, background): “Importantly, all EGF ligand family members are made as inactive transmembrane precursors that can undergo ectodomain proteolytic cleavage to release mature active growth factor (40, 44).”
• GC1118, an Anti-EGFR Antibody with a Distinct Binding Epitope and Superior Inhibitory Activity against High-Affinity EGFR Ligands (2015, background): “EGFR, a member of the ErbB or HER family of receptors, regulates various cellular processes including proliferation, differentiation, migration, and invasion (1).”
• Mechanism of activation and inhibition of the HER4/ErbB4 kinase. (2008, background): “[PubMed: 12648466] Cho HS, Leahy DJ. Structure of the extracellular region of HER3 reveals an interdomain tether.”
• ERBB receptors and cancer: the complexity of targeted inhibitors (2005, background): “Patients with cancer whose tumours have alterations in ERBB receptors tend to have a more aggressive disease, and one that is associated with factors that predict a poor clinical outcome, so ERBB receptors have been intensely pursued as therapeutic targets (reviewed in Ref”
• Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. (2005, background): “Ligand-induced signaling from receptor tyrosine kinases (RTKs) of the epidermal growth factor receptor (EGFR) family (also known as ErbB or HER) regulates many cellular processes, including proliferation, cell motility, and differentiation (Holbro and Hynes, 2004).”
• Activation of Abl tyrosine kinases promotes invasion of aggressive breast cancer cells. (2006, background): “HER-2/ErbB2) by receptor overexpression, presence of an autocrine growth loop, or mutation promotes breast cancer cell proliferation, survival, migration, invasion, and metastasis (17, 18).”
• Angiogenic signaling pathways and anti-angiogenic therapy for cancer (2023, background): “The EGF receptors consist of four proteins, EGFR (ErbB1), HER2 (ErbB2), HER3 (ErbB3), and HER4 (ErbB4),(146,147) which have an extramembrane binding domain, a single-chain transmembrane domain that contains a single hydrophobic anchor sequence, and an intramembrane tyrosine kinase binding domain tha”